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Background: Multidrug-resistant Acinetobacter baumannii, initially considered as having a poor clinical relevance, is
frequently isolated from infection cases in intensive care units. We describe the epidemiology of carbapenem
resistant A. baumannii (CRAB) in a general ICU in Palermo, Italy, from October 2010 to March 2011.
Findings: 58 of 61 isolates exhibited MICs for meropenem or imipenem ≥16 mg/L. Forty-nine carried blaOXA-23 and
two blaOXA-58 genes.
Five subtype clusters were detected by rep-PCR. Clusters D and E included 10 isolates that tested negative for the
carbapenem resistance genes. MLST attributed all isolates, but two, with sequence type (ST)2, whereas the two
remaining isolates with ST78.
The respiratory tract was the most common site of infection (26 out of 36 cases. 72.2%). A high infection related
mortality rate was observed (18 out of 35 patients, 51.4%). Nineteen patients tested positive for other multidrug
resistant organisms in addition to CRAB. In eight cases isolates belonging to distinct subtype clusters and/or with
distinct carbapenemase profiles were identified.
Conclusions: Carbapenem resistance was prominently driven by the dissemination of CRAB isolates belonging to
ST2, carrying the carbapenemase gene blaOXA-23. The colonization/infection of some patients by multiple strains is
suggestive of an endemic circulation of CRAB.Findings
Eighty-four consecutive CRAB isolates were recovered
from 36 patients, who were admitted to the ICU under
study between October 1, 2010 and March 31, 2011.
Based upon the inclusion criteria, 61 isolates were sub-
mitted to testing by PCR analysis to confirm the presence
of carbapenemase genetic determinants and molecular
typing by rep-PCR and, for representative isolates, by
MLST. A number of isolates from each patient ranging
between one and six was analyzed. The clinical samples
more prevalent were bronchial aspirates (n. 29), followed
by swabs from wound or tracheostomy (n. 8), blood (n. 7),
drainage fluids and tips of central venous catheter (n. 6
each).* Correspondence: caterina.mammina@unipa.it
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reproduction in any medium, provided the orAmong the 61 isolates, all (100%) were resistant to pen-
icillins(ampicillin,carbenicillin),cephalosporins(cefepime,
cefotaxime, ceftazidime), β-lactam-β-lactamase inhibitor
combinations and fluoroquinolones, whereas suscepti-
bility to aminoglycosides [amikacin, four (6.5%) suscep-
tible and two (3.3%) intermediate; gentamicin, one (1.6%)
susceptible and nine (14.7%) intermediate; tobramicin,
six (9.8%) susceptible and 12 (19.7%) intermediate) and
sulfamethoxazole-trimethoprim, nine (14.7%) susceptible]
was variable. Moreover, 50 (82.0%) and 11 isolates (18.0%)
tested, respectively, susceptible (MICs 0.5 – 2 mg/L) and
intermediate (MIC 4 mg/L) to tigecycline. Only colistin
showed 100% susceptibility with MICs ranging between
0.5 and 2 mg/L. Three strains only had a MIC for imi-
penem of 8 mg/L, whilst all the remaining isolates ex-
hibited MICs≥ 16 mg/L. Moreover, MICs for meropenem
were ≥ 16 mg/L for all, but three strains that showed
MICs of 4 and 8 mg/L in one and two cases, respectively.tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Dendrogram and computer-generated image of
rep-PCR banding patterns of the 61 CRAB isolates under study.
Similarity calculation is based upon the Kullback–Leibler method,
clustering is based upon the Unweighted Pair Group Method with
Arithmetic Mean (UPGMA).
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ence of carbapenemase genes. All isolates harboured a
blaOXA-51-like sequence. Forty-nine isolates had, in ad-
dition, blaOXA-23 and two only blaOXA-58 genes. No MBL
(IMP and VIM) gene sequence was detected. The two
OXA-58 isolates had MICs for imipenem ≥ 16 mg/L,
whereas for meropenem of 4 and 8 mg/L, respectively.
Ten isolates for which the imipenem MIC was ≥ 8 mg/L
had an unidentified carbapenem resistance mechanism.
All tested negative for the blaOXA-143 sequence. Presence
of ISAba1 in the promoter region of the blaOXA-51-like
gene was not investigated because of the inconsistent lit-
erature findings about its correlation with carbapenem
resistance and the possible involvement of alternative
mechanisms [1,2].
By adopting a similarity coefficient of ≥95% as the
threshold, all isolates, but one, clustered into five distinct
groups named A to E (Fig.1). Thirty-one out of 61 clus-
tered in a large group that included 29 blaOXA-23 and
the two blaOXA58 isolates. Two further subtype clusters,
B and C, included 6 and 13 OXA-23 producing isolates,
respectively. Strains belonging to the subtype clusters A,
B and C clustered at a 94% similarity level. Cluster D
and cluster E grouped eight and two isolates, respect-
ively, that tested negative for the carbapenem resistance
genes under investigation. One isolate only did not
cluster.
MLST attributed all isolates, but two, with sequence
type (ST)2, whereas the two remaining isolates belonged
to ST78.
There was not apparent relationship between sub-
type clusters, carbapenem resistance genes and the whole
resistance patterns or carbapenem resistance pheno-
type. Twelve out of 14 isolates showing susceptibility
or intermediate susceptibility to at least one aminogly-
coside were isolated in the first three months of the
investigation.
The main demographic and clinic characteristics of
the 36 patients are summarized in Table 1. The respira-
tory tract was the most common site of infection (26 out
of 36 cases, 72.2%). Moreover, a high infection related
mortality rate was observed (18 out of 35 patients with a
known outcome, 51.4%). From 19 patients other MDR
organisms in addition to CRAB were isolated from at
least one clinical sample (Table 1). Of special interest, eight
patients were co-colonized or co-infected at the same site
of CRAB by Klebsiella pneumoniae carbapenemase-
producing Klebsiella pneumoniae (KPC-Kp).
From 19 out of 36 patients two to six CRAB isolates
were consecutively identified in the period under study.
In 11 patients an indistinguishable CRAB isolate was re-
peatedly identified, unlike from the remaining eight
patients. In particular, three out of these patients yielded
isolates belonging to distinct subtype clusters and/orwith distinct carbapenemase profiles in different clinical
samples obtained up to 24 hours apart from each other;
alternatively, distinct isolates were sequentially identified
from the same or different clinical samples from five fur-
ther patients within intervals of time ranging between
four and seventy days (Table 2).
Background
The emergence of multidrug-resistant Acinetobacter
baumannii strains is posing severe challenges in many
clinical and post-acute care settings [3,4]. Initially consid-
ered as a colonizing bacterial species with poor clinical
relevance, it is being isolated more and more frequently,
especially in the intensive care units (ICUs), as the etio-
logical agent of serious infections, such as ventilator-
associated pneumonia (VAP), infections of bloodstream,
urinary tract, central nervous system and wounds [5]. A.
baumannii is typically selected by prior antimicrobial
Table 1 Demographic and clinical characteristics of the patients admitted in the period October 1, 2010 – March 31,















1 77/M thoracic trauma hypertension 39 cholecystitis none severe sepsis discharge
2 78/F respiratory failure lung cancer 31 LRTI none sepsis death
3 22/F polytrauma none 27 RTI none sepsis discharge
4 20/M cranial trauma none 42 pneumonia KPC-Kp severe sepsis death





30 pneumonia none septic shock death
7 34/F polytrauma none 45 LRTI P.
aeruginosa
sepsis discharge




9 73/M acute abdomen hypertension,
diabetes
38 peritonitis KPC-Kp septic shock death
10 50/M polytrauma none 44 pneumonia none severe sepsis discharge
















diabetes 71 pneumonia P.
aeruginosa
septic shock death
14 39/F respiratory failure autoimmune
disease, HCV
37 pneumonia ESBL-Kp septic shock death
15 60/M polytrauma hypertension 26 pancreatitis KPC-Kp septic shock death
16 60/M. third degree burns hypertension 71 complicated
SSTI
none septic shock death
17 70/M encephalitis hypertension 50 LRTI KPC-Kp severe sepsis death
18 75/F acute abdomen hypertension,
diabetes
32 peritonitis none u.i. u.i.
19 35/F polytrauma none 31 LRTI MRSA sepsis discharge
20 71/M stroke hypertension,
cerebral
vasculopathy
48 pneumonia none severe sepsis discharge
21 69/M AMI hypertension,
arrhythmia
56 pneumonia none septic shock death
22 60/M metabolic coma hepatopathy 71 LRTI none severe sepsis death













43 pneumonia none severe sepsis discharge
26 23/M polytrauma none u.i. BSI none septic shock death
27 18/M polytrauma none 30 LRTI KPC-Kp sepsis discharge
28 20/F respiratory failure SLE u.i. cystitis MRSE sepsis discharge
29 16/M cranial trauma epilepsy u.i. sinusitis none sepsis discharge
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Table 1 Demographic and clinical characteristics of the patients admitted in the period October 1, 2010 – March 31,
2011 and infected by CRAB (Continued)






31 28/M polytrauma none 17 LRTI P.
aeruginosa
sepsis discharge
32 75/M respiratory failure hypertension,
diabetes, CKD
27 pneumonia none septic shock death
33 58/M respiratory failure hypertension,
COPD,
hearth failure
34 pneumonia none severe sepsis discharge
34 41/M polytrauma none 38 LRTI MRSA severe sepsis discharge
35 87/F acute abdomen coagulopathy 45 pneumonia none severe sepsis discharge
35 64/M metabolic coma diabetes 71 pneumonia P aeruginosa septic shock death
AMI = acute myocardial infarction; BSI = bloodstream infection; CKD= chronic kidney disease; COPD= chronic obstructive pulmonary disease; LRTI = lower
respiratory tract infection; RTI = reproductive tract infection; SLE = Systemic Lupus Erythematosus; SSTI = skin and soft tissue infection; KPC-Kp = KPC
carbapenemase-producing Klebsiella pneumoniae; ESBL-Kp = Extended spectrum β-lactamases producing Klebsiella pneumoniae; ESBL-Ec = Extended spectrum
β-lactamases producing Escherichia coli; MRSA =methicillin resistant Staphylococcus aureus; MRSE =methicillin resistant Staphylococcus epidermidis; SAPSII =Mean
Simplified Acute Physiology Score II; u.i = unavailable information.
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ganism are difficult to treat, so leading to increasingly
rely on last resort molecules, such as polymyxins and
tigecycline for therapy [6]. Additionally, infections with
carbapenem-resistant A. baumannii (CRAB) organisms
may require discharged patients from acute hospitals to
be further managed in long-term care facilities (LTCFs)
or alternative post-acute care facilities and impose diag-
nostic, therapeutic and infection-control extra-costs [7,8].
Isolates of A. baumannii carry a naturally occurring
blaOXA-51 β-lactamase with a weak carbapenemase activ-
ity. Moreover, in a great proportion of isolates from dif-
ferent geographical areas, carbapenem resistance in A.
baumannii is mediated by the acquisition of a class B or
a class D carbapenem-hydrolyzing enzymes [9]. In Italy,
blaOXA-58 has been reported to be the most prevalent
OXA type carbapenem resistance gene, but a shift to-
wards blaOXA-23 that appears to be gradually substituting
blaOXA-58 has been recently described [10-12]. This
trend is likely to be related to the a higher carbapene-
mase activity of blaOXA-23 than blaOXA-58 that results in
higher carbapenem MICs and a consequent selective ad-
vantage. However, large scale data on the prevalence of
these genes throughout Italy are still scarce.
Genotypic characterization of A. baumannii has
shown that distinct clonal lineages, the so-called Euro-
pean (EU) clones I, II and III, are widely spread across
Europe and include strains that are usually multiresistant
(MDR) and responsible for epidemic and endemic oc-
currence of healthcare associated colonization and infec-
tion [3].
The objective of our study was to analyze the spread
and clonality of CRAB in a general ICU in Palermo, Italy,
by prospectively collecting and characterizing isolatesfrom infected patients who were being admitted to the
ICU over a six-month period from October 2010 to
March 2011. Medical records of patients from whom
CRAB was isolated were also retrospectively reviewed to
investigate their clinical outcomes.
Methods
Setting
The 2nd ICU of the ARNAS “Civico & Benfratelli” Gen-
eral Hospital of Palermo, Italy, is a 10-bed medical-
surgical Unit with approximately 430 admissions per
year. Preexisting medical and surgical conditions are
generally present in approximately 45% and 55%, re-
spectively, of all admissions. Organ failure is the leading
cause of admission (70%), followed by monitoring/wean-
ing from mechanical ventilation (30%). ICU mortality is
about 25%. Nurse to patient ratio is 1:2.
Consecutive CRAB isolates were recovered from all
patients who were admitted to 2nd Intensive ICU during
the six-month period October 1, 2010 – March 31,
2011. For the purpose of this study, the following inclu-
sion criteria were used for the selection of CRAB isolates
to be submitted to molecular typing: a) all the unique
isolates from different patients; b) replicate isolates
obtained from different clinical samples of the same pa-
tient up to 24 hours apart from each other; c) replicate
isolates obtained from the same patient more than 24
hours apart from each other from whatever clinical
sample.
CRAB isolates were isolated by standard methods and
identified by the Vitek 2 automated microbiology system
(bioMérieux, Marcy l'Étoile, France). Antimicrobial sus-
ceptibility testing was automatically undertaken by using
the commercial microdilution method Vitek 2. The
Table 2 Source, time of isolation, carbapenem MICs and molecular characteristics of the replicate CRAB isolates from
the eight patients yielding distinct isolates by subtype cluster and/or carbapenemase profile
patient* isolate date of isolation clinical sample MIC imipenem MIC meropenem PCR rep-PCR cluster ST
3 33 October 13, 2010 BA >= 16 >= 16 OXA-23 B 2
18 October 14, 2010 CVC >= 16 >= 16 OXA-23 A 2
4 51 October 25, 2010 BA >= 16 >= 16 OXA-23 singleton 2
29 December 1, 2010 CSF >= 16 >= 16 OXA-23 A 2
46 December 28, 2010 CSF >= 16 >= 16 OXA-23 C 2
9 19 November 22, 2010 peritoneal fluid >= 16 >= 16 OXA-23 A 2
32 November 22, 2010 BA >= 16 >= 16 OXA-23 B 2
53 November 23, 2010 blood >= 16 >= 16 negative D 2
15 13 December 27, 2010 BA >= 16 >= 16 OXA-23 A 2
17 January 7, 2011 drainage fluid >= 16 >= 16 OXA-23 A 2
30 January 8, 2011 blood >= 16 >= 16 OXA-23 A 2
16 January 19, 2011 drainage fluid >= 16 >= 16 OXA-23 A 2
14 January 29, 2011 wound swab >= 16 >= 16 OXA-23 A 2
61 February 14, 2011 blood 8 >= 16 negative E 78
17 44 January 3, 2011 BA >= 16 >= 16 OXA-23 C 2
11 January 7, 2011 blood >= 16 >= 16 OXA-23 A 2
23 48 January 24, 2011 drainage fluid 8 8 OXA-23 C 2
6 January 25, 2011 tracheostomy swab >= 16 >= 16 OXA-23 A 2
24 60 January 24, 2011 BA >= 16 >= 16 negative E 78
. 45 April 4, 2011 wound swab >= 16 >= 16 OXA-23 A 2
27 41 February 21, 2011 BA >= 16 >= 16 OXA-23 C 2
23 March 11, 2011 tracheostomy swab >= 16 >= 16 OXA-23 A 2
* patient’s numeric code refers to Table 1.
BA, bronchial aspirate; CVC, central venous catheter; CSF, cerebrospinal fluid.
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using the epsilometer test (Etest, AB Biodisk, Solna,
Sweden). Results were interpreted according to Clinical
and Laboratory Standards Institute (CLSI) criteria for
Acinetobacter spp [13]. Due to the lack of standardiza-
tion for A. baumannii, Enterobacteriaceae breakpoints
(≤2 μg/ml, susceptible; ≥8 μg/ml, resistant) were used
for interpreting the results of the tigecycline assays. The
control strain used was Escherichia coli ATCC 25922.
Characterization of CRAB isolates
To detect the presence of the most common carbapene-
mases, multiplex PCR was performed with primers that
anneal to blaOXA-51, blaOXA-23, blaOXA-24 and blaOXA-58
carbapenemases and the MBLs blaIMP and blaVIM, as
previously described [14,15].
The newly described gene blaOXA-143 was also searched
for [16].
To investigate the relationship among the CRAB iso-
lates collected during the study period, we used the rep-
PCR DiversiLab Microbial Typing SystemW (bioMérieux,
Marcy l'Étoile, France), which amplifies the regions be-
tween the non-coding repetitive sequences in bacterialgenomes. Extraction of DNA was performed using the
UltraCleanTM Microbial DNA Isolation Kit (Mo Bio La-
boratories, Inc., Carlsbad, CA, USA). Rep-PCR was per-
formed using the DiversiLab Acinetobacter kit. DNA
fragment separation and detection were done using the
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA) and results were analyzed and inter-
preted using the Kullback–Leibler method, as previously
reported [17]. Isolates were defined as genetically related
when ≥95% similarity was identified.
Genotyping by multilocus sequence typing (MLST)
was performed on representative CRAB strains selected
on the basis of clustering by rep-PCR and carbapene-
mase gene pattern. MLST was based on the sequence
analysis of the internal portions of seven housekeeping
genes (cpn60, fusA, gltA, pyrG, recA, rplB and rpoB). All
PCR amplifications were carried out under the following
conditions: 30 cycles (denaturation at 94 °C for 1 min,
annealing at 53 °C for 1 min, and extension at 72 °C for
1 min) preceded by a 5-min denaturation at 94 °C and
followed by a 10-min extension at 72 °C. PCR products
were sequenced in both directions by using BigDye
fluorescent terminators and primers on a 310 DNA
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dom). Details of the MLST scheme including amplifica-
tion and sequencing primers, allele sequences and STs
are available at Institute Pasteur's MLST Web site
(www.pasteur.fr/mlst).
Patients characteristics
The medical records of patients from whom CRAB was
isolated were retrospectively reviewed. The following
demographic and clinical data were obtained: age, gen-
der, reason for admission, underlying diseases, type of
infection and clinical manifestation, Mean Simplified
Acute Physiology Score II (SAPS II), isolation of other
MDR organisms, such as ESBL producing enterobac-
teria, vancomycin-resistant Enterococcus spp. (VRE) and
methicillin-resistant Staphylococcus aureus (MRSA), if
any, and outcome (dead/discharged).
This research conformed to local legislation and the
Helsinki Declaration and was approved by the ethics
committee of the ARNAS General Hospital “Civico &
Benfratelli, Palermo, Italy.
Discussion
CRAB is an healthcare serious issue in many European
countries. Literature shows that carbapenem resistance
rates are higher in southern Europe countries, such as
Turkey, Greece, Spain and Italy [18]. In Europe, out-
breaks are especially attributable to two main A. bau-
mannii clones (the so-called European clones I and II)
[19]. Clone II has been repeatedly reported in many
European countries, including Italy [5,8-10]. With regard
to the mechanism of carbapenem resistance in the Ital-
ian CRAB isolates, the spread of carbapenemases be-
longing to the molecular class D OXA enzymes has
been well documented [8-10,19-22].
Our study reveals that carbapenem resistance in the
ICU under study was prominently driven by the dissem-
ination of CRAB isolates belonging to ST2, the European
clone II, carrying the carbapenemase gene blaOXA-23. Of
interest, in comparison with the data obtained by previ-
ous studies conducted in Italy, as well also in other Medi-
terranean countries, the prevalence of blaOXA-58 carrying
isolates appears to be drastically lower [10,21,22]. Emer-
gence of an epidemic lineage carrying blaOXA-23 carbape-
nemase genes that is displacing a genetically closely
related CRAB clone encoding OXA-58 has been previ-
ously described in central Italy in a study involving 10
ICU [8]. The higher level resistance to carbapenems con-
ferred by OXA-23 is thought to be the success key of
OXA-23 carrying epidemic strains under the selective
pressure due to the increasing use of carbapenems,
mainly in combination with fluoroquinolones, forced in
turn by the epidemic spread of extended spectrum β-
lactamase producing organisms [23].Five subtype clusters were recognized by rep-PCR typ-
ing, with the first three – A to C – appearing to be
closely related and all belonging to ST2, so suggesting
the dissemination in the ICU of at least three well differ-
entiated clones. Isolates belonging to two of them, D
and E, tested negative for carbapenemase genes under
study, except for blaOXA-51-like. The two isolates belong-
ing to the subtype cluster E were attributed with ST78,
the so called “Italian clone”. This clone, after being iden-
tified firstly in Naples, Italy, in 2006–2007 as an emer-
ging epidemic clone, has been subsequently identified in
other cities of southern Italy, Catania, and northern,
Italy, Novara, accounting for a 13% proportion of iso-
lates [10,20-22]. More recently, the same clone has been
detected in ICUs, but also in home-care patients in Pa-
lermo, Italy [5]. Hence, ST78 seems to have largely dis-
seminated in Italy [20-22].
The detection in a same patient of CRAB isolates
belonging to different subtype clusters is a concerning
finding. An underestimation of the event is very likely
due to the routinely adopted microbiological diagnostic
procedures, that are not aimed at detecting a mixed
population of CRAB in patient or a clinical sample. Fur-
thermore, because an active culture surveillance pro-
gram was not in place in the ICU under study,
prevalence of CRAB positive patients/sites is likely to be
much higher and the relative proportion of the different
strains misrepresented. Nevertheless, identification of
distinct strains in an interval of time of 24 hours
strongly suggests that some patients could be simultan-
eously or sequentially colonized or infected by multiple
strains. The clinical and prognostic significance of such
a finding deserves further investigation. The variety of
subtype clusters could be likely interpreted as suggestive
of a situation of endemicity where the selective advan-
tage conferred by the high level carbapenem resistance
supports the epidemic spread of the ST2 lineage carrying
the blaOXA-23 determinant.
According with previous Authors, our data confirm
that CRAB is one of the most challenging Gram-
negative pathogens to control and treat in the ICUs,
resulting in serious infections and substantial mortality
[24,25]. Unfortunately, infection control measures used
to contain the CRAB dissemination can be very difficult
to be applied and substantially ineffective when it has
become endemic. On the other hand, compelling evi-
dence has accumulated about the contribution that con-
taminated surfaces make to the epidemic and endemic
transmission of many MDR organisms and above all
CRAB and MRSA [26,27].
Conclusions
Spread in the healthcare settings of CRAB is posing ex-
tremely challenging questions about the most effective
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ment as well as in the control and prevention of trans-
mission within and between the healthcare facilities. A
timely recognition and an accurate description of the
CRAB strains and clones that are spreading in a defined
area can contribute to obtain a more reliable epidemio-
logical picture and to devise effective and targeted con-
trol measures.
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